List of Aggrastat drug patents
Aggrastat is owned by Medicure.
Aggrastat contains Tirofiban Hydrochloride.
Aggrastat has a total of 1 drug patent out of which 0 drug patents have expired.
Aggrastat was authorised for market use on 14 May, 1998.
Aggrastat is available in solution;injection, injectable;injection dosage forms.
Aggrastat can be used as a dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs.
The generics of Aggrastat are possible to be released after 01 May, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(2 months from now) | |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1998
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs
Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic